[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595280":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":61,"collaborators":63,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":10,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":10,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"H. Lee Moffitt Cancer Center and Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Bruton's tyrosine kinase inhibitor treatment",null,"Patients treated with a Bruton's tyrosine kinase inhibitor.",[13],"Drug: Bruton's tyrosine kinase inhibitor",{"label":15,"type":10,"description":16,"interventionNames":17},"B-Cell Lymphoma 2 Protein Inhibitor treatment","Patients treated with a B-Cell Lymphoma 2 Protein Inhibitor.",[18],"Drug: B-Cell Lymphoma 2 Protein Inhibitor",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Bruton's tyrosine kinase inhibitor","BTKi",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"B-Cell Lymphoma 2 Protein Inhibitor","BCL2i",[15],[30],{"name":31,"affiliation":32,"role":33},"Sara Tinsley-Vance, PhD, APRN, AOCN","Moffitt Cancer Center","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Daniel Lastorino","CONTACT","813-745-0092","Daniel.Lastorino@moffitt.org",[41],{"facility":32,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Tampa","Florida","33612","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-82.45843,27.94752,{"lat":52,"lon":51},[55,56,59],{"name":31,"role":33,"phone":10,"phoneExt":10,"email":10},{"name":57,"role":58,"phone":10,"phoneExt":10,"email":10},"Dorothie Durosier Mertilus, PhD","SUB_INVESTIGATOR",{"name":60,"role":58,"phone":10,"phoneExt":10,"email":10},"Richie Reich, PhD",{"type":62,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[64,67],{"name":65,"class":66},"National Comprehensive Cancer Network","NETWORK",{"name":68,"class":69},"AstraZeneca","INDUSTRY","100595280","predictors-of-health-related-qol-in-adults-with-cll-or-small-lymphocytic-lymphoma-100595280",false,"NCT07030400","Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma","Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Inclusion Criteria:\n\n* All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +\u002F- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.\n* Subjects must be able to read and speak English or Spanish at the 8th grade level.\n\nExclusion Criteria:\n\n* Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.","ALL","18 Years",{"count":80,"type":81},100,"ESTIMATED","OBSERVATIONAL","The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.",[85,86],"Small Lymphocytic Lymphoma (SLL)","Chronic Lymphocytic Leukemia (CLL)","2026-03-31",{"date":89,"type":90},"2026-04-01","ACTUAL",{"date":92,"type":90},"2025-07-17",{"date":94,"type":81},"2028-06",{"name":5,"class":6},1]